New agents for prostatic carcinoma.
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; C016358:2,4-diamino-5-adamantyl-6-methylpyrimidine; D004961:Estramustine; D000218:Adamantane; D002945:Cisplatin; D005472:Fluorouracil